Current PSA level-Between 4 to 10 - Page 3 of 7 Posts on Medivizor
Navigation Menu

Current PSA level-Between 4 to 10 Posts on Medivizor

The role of active surveillance for men with intermediate-risk prostate cancer

The role of active surveillance for men with intermediate-risk prostate cancer

Posted by on Dec 19, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the role of active surveillance in the management of intermediate-risk prostate cancer. Researchers concluded that active surveillance is a safe management method for selected patients with favorable intermediate-risk disease. Men with more aggressive cancer cells may benefit from active treatment early on. Some...

Read More

Can biopsies guided by multiple imaging techniques better detect disease progression?

Can biopsies guided by multiple imaging techniques better detect disease progression?

Posted by on Dec 1, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the benefit of biopsies guided by multiple imaging techniques (scans that provide images of the interior of the body) in men managed with active surveillance. Researchers reported improved detection rates of disease progression when biopsies were guided by multiple imaging techniques. Some background Many men with...

Read More

Searching for men with low- to intermediate-risk prostate cancer to test precise radiation therapy guided by an imaging technique

Posted by on Nov 14, 2016 in Prostate cancer | 0 comments

In a nutshell This trial aims to examine stereotactic radiosurgery guided by an imaging technique in treating low- to intermediate-risk prostate cancer. The main outcome to be investigated is treatment-related side effects and treatment response. The trial is recruiting in Ohio (USA). The details Stereotactic radiosurgery (SRS) uses a specially...

Read More

Risk factors, unfavorable disease and the implications for active surveillance in early-stage prostate cancer

Risk factors, unfavorable disease and the implications for active surveillance in early-stage prostate cancer

Posted by on Oct 17, 2016 in Prostate cancer | 0 comments

In a nutshell The authors aimed to determine the risks of unfavorable disease and predictors of adverse outcomes in men with Gleason score 3 + 4 prostate cancer and how this would affect active surveillance. The authors concluded that active surveillance is a potential treatment option in men with Gleason score 3+4, low PSA scores and low-stage...

Read More

Examining the benefits of combining hormone therapy and radiation therapy

Examining the benefits of combining hormone therapy and radiation therapy

Posted by on Jul 18, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the evidence for combining androgen deprivation therapy (ADT) with radiation therapy for the treatment of high-risk localized prostate cancer. Authors concluded that the combined therapy approach was associated with a survival advantage for intermediate- and high-risk patients.  Some background ADT is a type...

Read More

The effect of combined radiation and hormone therapy on long-term fatigue

Posted by on Jul 18, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the effect of combined radiation and hormone therapy on long-term fatigue. Researchers reported severe fatigue during and up to 4 years after treatment. Men with increased cancer markers and symptoms were more likely to report higher fatigue levels. Some background Radiation therapy and hormone therapy are often...

Read More

Searching for overweight men with low-risk prostate cancer undergoing active surveillance

Posted by on Jun 13, 2016 in Prostate cancer | 0 comments

In a nutshell This phase 3 trial aims to evaluate the benefit of a diet and exercise program in overweight men with low-risk prostate cancer. The main outcome to be investigated is a change in blood sugar metabolism in prostate cancer cells. The trial is recruiting in Seattle (Washington), USA. The details Low-risk prostate cancer is often managed...

Read More

Searching for men undergoing active surveillance for low risk prostate cancer

Posted by on Apr 25, 2016 in Prostate cancer | 0 comments

In a nutshell This phase III trial aims to evaluate if metformin (Glucophage) can delay the time to progression in men with low-risk prostate cancer. The main outcome to be investigated is disease progression based on the need for treatment or biopsy results. The trial is recruiting in several locations in Canada. The details Metformin is a drug...

Read More

Is abiraterone acetate also suitable for older men with castration resistant prostate cancer?

Is abiraterone acetate also suitable for older men with castration resistant prostate cancer?

Posted by on Mar 25, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined abiraterone acetate (Zytiga) as a treatment option for older men with metastatic castration-resistant prostate cancer. Researchers concluded that abiraterone acetate improves overall survival in younger as well as older men with metastatic castration resistant prostate cancer. Some background...

Read More